Systemic radionuclide therapy in pain palliation.

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmaceutical Therapy

Background:

• Bone metastases cause significant pain and reduced quality of life in cancer patients.
• Radiopharmaceutical therapy offers a palliative treatment option for painful bone metastases.

Purpose of the Study:

• To evaluate the efficacy and toxicity of rhenium-188 hydroxyethylidene diphosphonate (188Re-HEDP), rhenium-186 hydroxyethylidene diphosphonate (186Re-HEDP), and strontium-89 (89Sr) in palliating painful bone metastases.
• To assess the impact of these radiopharmaceuticals on pain symptoms, quality of life, and bone marrow function.

Main Methods:

• A comparative study involving 64 patients with breast and prostate cancer experiencing painful bone metastases.
• Patients were treated with either 188Re-HEDP, 186Re-HEDP, or 89Sr.
• Pain, quality of life (Karnofsky Performance Status), and bone marrow function (blood counts) were assessed before and after a 12-week therapy period.

Main Results:

• Significant pain relief was reported by 77% of patients treated with 188Re-HEDP, 67% with 186Re-HEDP, and 72% with 89Sr.
• 16-17% of patients in each treatment group became pain-free and discontinued analgesics.
• All radiopharmaceuticals showed acceptable bone marrow toxicity, with reversible effects observed within 12 weeks; 188Re-HEDP demonstrated a statistically significant improvement in Karnofsky Performance Status.

Conclusions:

• 188Re-HEDP, 186Re-HEDP, and 89Sr are effective radiopharmaceuticals for palliating painful bone metastases.
• These treatments offer significant pain relief and improvement in quality of life with a favorable safety profile.
• 188Re-HEDP showed a statistically significant improvement in patient performance status.